May
Medicinal Chemistry
&
Drug Discovery Biology
Strategy Meeting West Coast USA 2026
What makes our strategy meetings unique?
Roundtable Discussions
Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.
Unrivalled Networking
With senior delegation from big pharma and innovative biotech from across the West Coast, you can network with peers from different locations, all in one place.
Personalised Agenda
Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.
Solutions to your Problems
We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.
Industry Researched Topics
We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.
Senior Decision Makers
The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.
Our Facilitators
Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at Medicinal Chemistry Strategy Meeting.
Bishnu Nayak
Senior Director/Site Head Neologics Bio

David Bredt
Founder, Chief Scientific Officer Rapport Therapeutics

David Weitz
Chief Executive Officer and Founder Syrna Therapeutics

Devin Swanson
Principal Scientist External Innovation Janssen


Igor O. Nasonkin
CEO Phythera Therapeutics

Leo Kirkovsky
Director, Clinical Assay Group Pfizer

Mark Nelson
Vice President, Chemistry and Co-Founder Neumedics


Mehran Moghaddam
CEO OROX Biosciences, Inc.

Neil Raheja
Founder, President, and COO Venquis Therapeutics

Sampath Kumar Anandan
Vice President of Discovery Inipharm

Sanjeev Thohan
Scientific Advisory Board Member Cogentis Therapeutics/ Phoenix Molecular Designs

Sean Sullivan
Vice President Arcturus Therapeutics

Shicheng Guo
Senior Director of Translational Genetics and Data Science Arrowhead PharmaceuticalsOur Past Facilitators
OUR AGENDA
See Which Topics Are Up For Discussion
Roundtable Tracks
1AI-Driven Design for Challenging Modalities & “Hard” Targets (e.g. Kinases, Allosteric Sites, Undruggables, Protein Degraders)
-Sanjeev Thohan
Scientific Advisory Board Member
Cogentis Therapeutics/ Phoenix Molecular Designs
DMPK / ADME & Toxicology
End‑to‑End Small Molecule Drug Development via Integrated Discovery, DMPK, and Manufacture
Chemical Biology, Targeted Protein Degradation & Undruggables
The Future of Undruggables: Integrating AI, Chemoproteomics, and Targeted Degradation
Target Identification/ Lead Optimization
Structure Enabled Design Transforming Early Discovery and Fast Tracking Lead Optimization
-David Bredt
Founder, Chief Scientific Officer
Rapport Therapeutics
Integrated Drug Discovery
Integrated Drug Discovery to API Synthesis
-Mark Nelson
Vice President, Chemistry and Co-Founder
Neumedics
Private Equity, Venture Capital & Strategic Partnerships In Drug Discovery
Partnering to Shorten the Discovery and Development Timeline (Topic TBC)
-Devin Swanson
Principal Scientist External Innovation
Janssen
Roundtable Tracks
2Converging Data, Science, and Automation: How Unified Digital Frameworks Accelerate Multi-Modal Drug Discovery
SPONSOR
DMPK / ADME & ToxicologyBreaking Bottlenecks in Preclinical Development: Integrated ADME, Safety and Bioanalysis Solutions for Novel Modalities
SPONSOR
Chemical Biology, Targeted Protein Degradation & UndruggablesThe Next Generation of Degrader Architectures Reshaping Undruggable Targets in 2026 – Beyond PROTACs 2.0
SPONSOR
Target Identification/ Lead OptimizationStreamlining Chemistry, Biology, and Analytics: Integrated Platforms for Faster Hit-to‑Lead and Lead-to‑Preclinical Transitions
SPONSOR
Integrated Drug DiscoveryHolistic Risk Management: From Early‑Stage Discovery to Preclinical Development — Minimizing Failures through Integrated Workflows
Revvity Signals
Private Equity, Venture Capital & Strategic Partnerships In Drug DiscoveryThe Role of Machine Learning and AI-Powered Data Platforms in Shaping Future Investment Decisions and Portfolio Strategy
SPONSOR
Roundtable Tracks
3AI-Enabled Design for Complex Biology: CNS Targets, RNA Therapeutics, Multi-modal / Multitarget Drugs, Personalized Medicine (Topic TBC)
-Shicheng Guo
Senior Director of Translational Genetics and Data Science
Arrowhead Pharmaceuticals
DMPK / ADME & Toxicology
Optimizing Drug Metabolism & Pharmacokinetics at Scale: Modern DMPK Capabilities for Predictive Preclinical Development
Chemical Biology, Targeted Protein Degradation & Undruggables
Targeting the Undruggable at Scale Integrating Chemical Biology Deep Learning and Next-Gen Screening
Target Identification/ Lead Optimization
The New Frontier of Hit Identification: High-Dimension Screens, DNA Encoded Libraries & Virtual Exploration
Integrated Drug Discovery
Integrating Novel Modalities Into End to End Drug Discovery Pipelines(Topic TBC)
-Sampath Kumar Anandan
Vice President of Discovery
Inipharm
Private Equity, Venture Capital & Strategic Partnerships In Drug Discovery
Partnering Science and Strategy: Translating Integrated Discovery Pipelines into Value for Investors, Collaborators, and Patients
Roundtable Tracks
4The Autonomous Chemist: Large Chemical Models and Self-Driving Optimization Loops
DMPK / ADME & Toxicology
ADME & Safety for RNA, Oligonucleotides, and LNP Platforms: What Chemists Must Know
Chemical Biology, Targeted Protein Degradation & Undruggables
Hit-to-Lead Strategies for PROTACs, Molecular Glues & Targeted Protein Degradation
Target Identification/ Lead Optimization
Discovery in RNA & Oligonucleotide Therapeutics
Integrated Drug Discovery
From Target to Tablet: End‑to‑End Small Molecule Drug Development via Integrated Discovery, DMPK, and Manufacture (Topic TBC)
-Igor Nasonkin
Co-founder & CEO
Phythera Therapeutics
Private Equity, Venture Capital & Strategic Partnerships In Drug Discovery
Enabling Biotech and Virtual Pharma — Outsourced R&D, Manufacturing, and Testing for Lean, High‑Velocity Drug Developers
-Mehran Moghaddam
CEO
OROX Biosciences, Inc.
Aligning Capital, Capability, and Curiosity: The Future of Venture and Partnership in Drug Discovery
Reasons To Attend Our Strategy Meetings
Fully Interactive Format
There’s only so much you can learn from presentations and lectures. Instead, our interactive Roundtable Discussions let you debate the topics that really matter.
Senior Decision Makers
All our Strategy Meetings are aimed at director-level and above. Discover how your peers are tackling the industries biggest challenges and have your thoughts heard.
Personalised Agendas
Pick the roundtable discussions that you want to be part of. Simply choose your sessions and we’ll create a personalised agenda just for you.
Private and Intimate Networking
Small group discussions, private meetings, networking drink – however you choose to make those important connections, our Strategy Meetings have the solution.
Explore Highlight From The Past Events
Gain valuable insights, discover innovative solutions and connect with industry leaders through snapshots of our most successful gatherings.
Watch to hear what your colleagues had to say…












Hotel & Venue
Hard Rock Hotel San Diego
You’re the main act in San Diego. At Hard Rock Hotel, we immerse you in our musical amenities, world-class service, and intoxicating location in downtown San Diego. Tour the Gaslamp Quarter on an Electra bike and walk a block to Petco Park.
Hotel Details Map & Directions Parking









Here To Help
Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.
Medicinal Chemistry
Drug Discovery Biology
Hard Rock Hotel San Diego






























